Abstract: Novel antibiotic stalobacins A to I having physico-chemical properties as shown in Tables 1 to 4 are provided, which are excellent antibiotics showing marked effects on Gram-positive bacteria.

Abstract: The present invention relates to methods and compositions for the control and prevention of helmintic, arthropod ectoparasitic and acaridal infections, in warm-blooded animals, such as meat-producing animals, and poultry, by administering to said animals a therapeutically or prophylactically-effective amount of new agents designated LL-F28249.alpha., .beta., .gamma., .delta., .epsilon., .xi., .eta., .theta., .iota., .kappa., .lambda., .mu., .upsilon. and .omega., or mixtures thereof. The invention also relates to methods for the control of plant nematode infestations and other insecticidal activities. These novel agents are produced via a controlled conditioned microbiological fermentation using Streptomyces cyaneogriseus ssp. noncyanogenus, designated LL-F28249 and having deposit accession number NRRL 15773.

Abstract: This invention relates to antibiotic LL-D37187.alpha. derived from the microorganism Streptomyces which is useful as an antibacterial agent.

Abstract: Described is a new immunosuppressant, L-687,819, a C-31 demethylated derivative of L-683,795 (FK-523), produced under fermentation conditions utilizing the new mutant microorganism, Streptomyces hygroscopicus subsp. ascomyceticus (Merck Culture Collection MA 6646) ATCC No. 53855, being a blocked mutant of Streptomyces hygroscopicus subsp. ascomyceticus (MA 6475) ATCC No. 14891. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.

Abstract: The invention is drawn to an antibiotic produced by Bacillus subtilis ATCC 55422 having a nominal molecular weight of 580 and the empirical formula C.sub.35 H.sub.48 O.sub.7, or a salt thereof. The antibiotic is useful in inhibiting the growth of bacteria, including Escherichia, Klebsiella, Proteus, Serratia, Bacillus and Staphylococcus.

Abstract: The present invention relates to methods and compositions for the control and prevention of helmintic, arthropod ectoparasitic and acaridal infections, in warm-blooded animals, such as meat-producing animals, and poultry, by administering to said animals a therapeutically or prophylactically-effective amount of new agents designated LL-F28249.alpha., .beta., .gamma., .delta., .epsilon., .xi., .eta., .theta., .iota., .kappa., .lambda., .mu., .nu. and .omega., or mixtures thereof. The invention also relates to methods for the control of plant nematode infestations and other insecticidal activities. These novel agents are produced via a controlled conditioned microbiological fermentation using Streptomyces cyaneogriseus ssp. noncyanogenus, designated LL-F28249 and having deposit accession number NRRL 15773.

Abstract: New glycopeptide antibiotic A80407, comprising A80407A and A80407B, is produced by Kibdelosporangium philippinensis strains NRRL 18198, and NRRL 18199 or A80407-producing mutants of these strains. The A80407 antibiotics have excellent activity against Gram-positive bacteria, increase feed-utilization efficiency in monogastric and ruminant animals and improve weight gains in animals.

Abstract: The present invention relates to methods and compositions for the control and prevention of helmintic, arthropod ectoparasitic and acaridal infections, in warm-blooded animals, such as meat-producing animals, and poultry, by administering to said animals a therapeutically or prophylactically-effective amount of new agents designated LL-F28249.sub..alpha., .beta., .gamma., .delta., .epsilon., .xi., .eta., .theta., .tau., .kappa., .lambda., .mu., .nu., and .sub..omega., or mixtures thereof. The invention also relates to methods for the control of plant nematode infestations and other insecticidal activities. These novel agents are produced via a controlled conditioned microbiological fermentation using Streptomyces cyaneogriseus ssp. noncyanogenus, designated LL-F28249 and having deposit accession number NRRL 15773.

Abstract: A non-aqueous pharmaceutical liquid suspension having improved bioavailability for oral administration comprises an active ingredient suspended in an edible, non-aqueous carrier vehicle such as an oil, wherein the active ingredient is in the form of controlled release particles containing the active ingredient and optionally an excipient in intimate admixture with at least one non-toxic polymer, the particles being coated with, distributed through or adsorbed onto said polymer, and the particles further having an average size in the range 0.1 to 150 microns and a predetermined release of active ingredient.

Abstract: The AB-011 Antibiotics and the main components thereof: AB-011a and AB-011b, obtained by the controlled aerobial cultivation of Streptomyces s.p. NCIB 12629 in an aqueous nutrient cultivation medium. The AB-011 Antibiotics show a biological activity, and in particular an antifungal activity.

Abstract: In vitro results indicate that trimethoprim may be ineffective against S. enteritides. However, in vivo results show that trimethoprim alone and in combination with polymyxin B sulfate is effective on S. enteritidis infections in poultry.

Abstract: The AB-021 Antibiotics and the main components thereof: AB-021a Antibiotic and AB-021b Antibiotic, obtained by means of the controlled aerobial cultivation of Streptomyces sp. NCIB 40068 in an aqueous nutrient cultivation medium, are disclosed.The AB-021 Antibiotics show a biological activity against pathogenous fungi of agrarian cultivations, of human pathogenous fungi and of bacteria.

Abstract: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.

Abstract: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.

Abstract: A composition suitable for topical application to mammalian skin or hair comprising an amount of a cell-free supernatant from a culture of dermal papilla cells sufficient to increase hair growth in mammals.

Abstract: An antitumor antibiotic designated BMY-42428 is produced by fermentation of Actinomadura madurae ATCC-53806. The BMY-42428 antibiotic exhibits both antimicrobial and antitumor activities.

Abstract: Preparations of drugs in admixture with certain ligands are described which, when administered to animals or humans, are less toxic than conventional drug preparations. Although the toxicity of the drug-ligand preparations described is greatly reduced, the drug retains pharmacological activity.

Abstract: A new species of Micromonospora, in particular Micromonospora spartanea ATCC 53803, is described. The species produces antifungal compounds spartanamicins A and B. Methods for the production, isolation and characterization of the compounds are described. The compounds contain deoxy-L-fucose, as well as another hexose and an amino sugar.

Abstract: A novel compound, DC-107, is produced by culturing a microorganism belonging to the genus Streptomyces. It is useful as a medicine because of its antibacterial and anti-tumor activity.

Abstract: A test reagent for detecting fibrin monomers in blood, comprises an antibiotic of a pyrrole amidine series as a precipitant, introduced in a buffer solution. A method of detecting fibrin monomers in blood, comprises the steps of mixing venous blood with an anticoagulant, centrifuging the mixture of the venous blood with the anticoagulant, removing a citrate plasma, using an antibiotic of a pyrrole amidine series as a precipitant, and evaluating a precipitation reaction which takes place thereby.

Abstract: This invention relates to a process for preparing an antibiotic D788-7 wherein, after culturing carborubicin-producing bacteria, the obtained culture liquid is extracted in acidic conditions while stirring to be absorbed to synthetic resin, followed by desorption from the resin and elution with acetone and the resulting acetone solution containing carborubicin is converted into an antibiotic D788-7 by photo radiation, for obtaining D788-7 in the purified form from the reaction solution. The production yield for D788-7 is extremely high and its use as an antitumor agent can be made possible.

Abstract: FR-900493 is a compound of molecular formula C.sub.20 H.sub.33 N.sub.5 O.sub.11 which may be recovered from Bacillus cultures, possesses antimicrobial activity, and may be used for the treatment and prevention of infectious diseases in humans and animals.

Abstract: A composition and formulation for use in covering and healing of wounds to the body, the formulation consisting of a mixture of a tissue compatible, water-based acrylic adhesive and collagen. The formulation comprises from between about 0.1% and 10% of collagen (dry basis), with the adhesive component preferably containing about 50% solids, balance water.

Abstract: The antibiotic of the formula: ##STR1## wherein R is ##STR2## The antibiotic is useful for the treatment of swine dysentery and for promoting growth and/or increasing the efficiency of food utilization in poultry, swine and ruminants.

Abstract: A compound of the formula ##STR1## wherein R.sup.1 and R.sup.4 are independently amino or an organic residue bonded through nitrogen, R.sup.2 is hydrogen or alkyl which may be substituted, R.sup.3 is hydrogen or a protecting group and R5 is hydroxyl which may be substituted or amino which may be substituted or salts thereof; with the proviso that when R.sup.1 is amino, leucylamino, acetylamino or benzyloxycarbonylamino, R.sup.3 is hydrogen, methyl or 2-tettrahydropyranyl, R.sup.4 is amino, acetylamino or benzyloxycarbonylamino and R.sup.5 is hydroxyl which may be substituted or amino which may be substituted, R.sup.2 is alkyl which may be substituted, has antibacterial activities against drug-resistant bacteria and therefore can be useful as a chemotherapeutic drug for bacterial infections in mammals.

Abstract: A sulfated polysaccharide DS4152 useful as an angiogenesis inhibitor or antitumor agent is provided selectively. As the sodium salt, it has the following physicochemical characteristics. Molecular weight by the gel filtration method: 29,000.+-.3,000. Elemental analysis: C: 24.42-25.76%, H: 3.34-3.98%, N: 0.51-0.89%, S: 10.6-11.7% and P: 0.77-1.06%. Sugar and protein contents: Sugar content (%): 57.+-.3 (by phenol sulfuric acid method; standard: galactose). Protein content (%): 1.+-.0.5 (by the Lowry-Folin's method; standard: bovine serum albumin). Specific rotatory power [.alpha.].sub.D.sup.25 : -37.degree..+-.1.degree. (0.5% aq. solution). Characteristic absorption bands in infrared absorption spectrum: 1240, 840 (shoulder), 810 (cm.sup.-1 ; KBr).

Abstract: Agent for preventing plant virus diseases such as tobacco mosaic viruses, potato viruses, cucumber mosaic viruses, etc. of this invention is obtained from a new agent containing polylysine as an active component. Polylysine can be used .alpha.-polylysine or .beta.-polylysine.

Abstract: Cultivation of a strain of the microorganism Micromonospora sp. A.T.C.C. No. 53481, yields the novel antibiotic substance glyphomicin, which is a mixture of glyphomicin A and glyphomicin B.

Abstract: Methods and products for overcoming bacterial resistance to tetracycline-type antibiotics by inhibiting the plasmid-mediated active efflux system for tetracycline in the resistant bacterial cell by administering with tetracycline efflux system blocking agents, thereby increasing the sensitivity of the resistant cell to tetracycline type antibiotics.

Abstract: This invention relates to methods and compositions for the control of protozoal infections in warm-blooded animals by administering to said animals a protozoacidally-effective amount of a new antibiotic designated LL-E19020.alpha., LL-E19020.beta. or a pharmaceutically and prophylactically acceptable salt thereof. The new antibiotics are produced by microbiological fermentation under controlled conditions using a new strain of Streptomyces lydicus subspecies tanzanius or mutants thereof.

Abstract: Novel substances having carcinostatic and immunostimulating activity, which are obtained from a culture or its supernatant fluid prepared by culturing bacteria belonging to Fusobacterium genus. Said substances are useful for the treatment of cancerous diseases lower warm-blooded animals. This disclosure concerns such substances and a process for preparing the same and a carcinostatic agent containing the same.

Abstract: 3,3'-Neotrehalosadiamine antibiotic is prepared by fermentation of B. pumilus K169-B91 (ATCC No. 53206) in a nutrient medium preferably comprising soybean meal, corn starch, calcium carbonate and magnesium sulfate. The antibiotic and pharmaceutically acceptable salts and hydrates thereof and compositions containing these are useful to treat bacterial infections in mammals.

Abstract: Penicillin or related substances are added during the course of the cultivation of a streptococcus to recover SPF-100 from the culture broth. SPF-100 exhibits a broad range of molecular weight and may be classified into SPF-1 and SPF-2.SPF-100 has a direct cancericidal effect and an immunoactivation effect.

Abstract: Antibiotic FR-900451 is produced by Streptomyces griseorubiginosus No. 43708 (FERM BP-699).

Abstract: Antitumor agents LL-D49194.alpha..sub.1, LL-D49194.beta..sub.1, LL-D49194.beta..sub.2, LL-D49194.beta..sub.3, LL-D49194.gamma., LL-D49194.delta., LL-D49194.epsilon., LL-D49194.xi., LL-D49194.eta., LL-D49194.omega., LL-D49194.omega..sub.2 and LL-D49194.omega..sub.3.

Abstract: Novel antibiotic SF-2288 is produced by fermentation of an actinomycete belonging to the genus Actinomadura in nutrient medium. Based on its physico-chemical and biological properties, antibiotic SF-2288 possesses an excellent antimicrobial activity against Gram-positive and Gram-negative microorganisms and antiviral activity.

Abstract: A substance TH69E having the following characteristics: (a) elementary analysis: C: 24.25%, H: 4.46% and N: 6.55%; (b) molecular weight: about 60,000.+-.15,000 (Biogel P-Series Column); (c) color: white amorphous powder; (d) decomposition point: 180.degree. C. (as determined by a capillary method with use of Silicone Oil WF-30--the color changes to brown); (e) ultraviolet absorption spectrum: as shown in FIG. 1 of the drawings; (f) infrared absorption spectrum: as shown in FIG. 2 of the drawings; (g) pH: 6.7 to 7.1 in an aqueous solution; (h) solubility: soluble in water, and insoluble in ethanol, acetone, n-hexane, n-butanol and phenol; and (i) color reactions: phenol-sulfuric acid reaction, anthrone reaction, Molisch reaction, orcinol-hydrochloric acid reaction, Ninhydrin reaction being positive, and Elson-Morgan's reaction being negative.

Abstract: A novel proteinous substance KUP-PC, which is produced by culturing proteinous substance KUD-PC producing organisms belonging to the genus Streptosporangium. KUD-PC increases the antitumor activity of the anti-tumor substance, sporamycin.

Abstract: A polysaccharide PS-A obtained from plants belonging to the genus Epimedium and having the following physicochemical properties, a process for preparation thereof and use as phylactic and immunostimulating agents comprising the polysaccharide PS-A as an effective component:1. Elementary analysis: C=40.92; H=6.17; Ash=very small;2. Molecular weight: 75,000.+-.25,000 (average molecular weight);3. Decomposition point: 205.degree. C.;4. pH: 7.0 (solution of 100 mg of PS-A in 50 ml of water);5. Specific rotatory power: [.alpha.].sub.D.sup.19 =-23.6.degree. (in H.sub.2 O, c=0.527);6. Infrared absorption spectrum: .nu..sub.max.sup.KBr (cm.sup.-1)/3400, 2900, 1620, 1400, 1230, 1060;7. Ultraviolet absorption spectrum: Maximum absorption is not recognized in the range of 240-400 nm.;8. Outward form: White or faint brown, amorphous powder;9. Solubility:(a) Soluble in water;(b) Insoluble in methanol, ethanol, acetone, ethyl acetate, diethyl ether, hexane and chloroform;10.

Abstract: .beta.-Galactosidase inhibitors GT-2558, GT-2558-A, and GT-2558-B produced by a strain Streptomyces lydicus PA-5726, and their derivatives, acetyl-GT-2558-A and acetyl-GT-2558-B, useful as diagnostatic aid in .beta.-galactosidase deficiency, used in purification of enzymes, in research of new .beta.-galactosidase, in controlling sweetness of lactose-containing foods and in fermentation industry.

Abstract: Orally administered compositions for altering lipid metabolism are described herein, these compositions containing an effective dose of endomycin. Also the method of altering lipid metabolism including reducing and controlling the blood cholesterol level, is described herein.

Abstract: This invention relates to a unique drug delivery system for delivering drugs to a body cavity. The drug delivery system comprises a medicament and a polymer such that the drug delivery system is a liquid at room temperature but forms a semi-solid or gel at the body temperature in the body cavity.

Abstract: Novel TF-2 substances having carcinostatic and immunostimulating activity, which are obtained from a culture or its supernatant fluid prepared by culturing bacteria belonging to Fusobacterium genus. Said substances are useful for the treatment of cancerous diseases of the mammals including human being. This disclosure concerns such substances and a process for preparing the same and a carcinostatic agent containing the same.

Abstract: This invention describes the application of selected polymers as novel drug delivery systems which use the body temperature and pH to induce a liquid to gel transition of the polymer which contains a drug or therapeutic agent therein. The goal of such a delivery system is to achieve a greater degree of bioavailability or sustained concentration of a drug.

Abstract: This invention relates to a unique drug delivery system for application to the skin which drug delivery system is a liquid at room temperature, but when administered topically to the skin becomes a semi-solid or gel when warmed by the body.

Abstract: Present invention provides a unique drug delivery device for delivering drug by injection into a body. The drug delivery system comprises the drug and polymer which is a liquid at room temperature and a semi-solid or gel at the body temperature.

Abstract: A physiologically active novel substance designated as Mutastein is disclosed, which has the following specific physiological properties:(1) it has a molecular weight of at least 200,000, and when subjected to gel-filtration with Sephadex G-100 and Sephallose 6B, it will be eluted in the void volume;(2) its ultraviolet spectrum: FIG. 1;(3) its infrared spectrum: FIG. 2;(4) it has a proteinous nature and contains about 10% of saccharide;(5) it is soluble in water and a saline solution, but it will be salted out from a saturated solution containing about 30% of ammonium salfate; and it is insoluble in acetone, ethanol, ethylacetate and benzene,(6) it dissolves in a buffer solution having a pH 7 or over, but it precipitates at a pH of from 3 to 3.5,(7) it is stable when heat-treated at pH 9, at 100.degree. C. for 10 minutes,(8) its elementary analysis: C: about 44%, H: about 7%, and N: about 12%,(9) its color reactions: Phenol-surfuric acid color reaction (orange), and Folin's color reaction (blue).

Abstract: A process for preparing a coherent porous collagen sheet material is comprised of forming natural insoluble particulate collagen in substantially pure form and suspending the particulate collagen in a weak aqueous organic acid solution while maintaining the collagen in particulate form. The suspension is freeze-dried to form a coherent porous native collagen sheet material which is useful as a wound dressing, burn dressing, hemostatic sheet or the like.

Abstract: Macromolecular reconstituted collagen is prepared by treating natural insoluble collagen with an aqueous solution comprised of an alkali sulfate salt and an alkali metal hydroxide for at least 48 hours to saponify fats suspended within the natural insoluble collagen. The fat free collagen is then treated with an aqueous solution comprised of an alkali metal sulfate for at least four hours to stabilize the interfibular bonds between individual polypeptide chains. The collagen is then dissolved in an aqueous acid solution and frozen at a rate of -20.degree. C./hour. The frozen collagen is vacuum dried at 10.sup.-3 to 10.sup.-5 torr for at least 16 hours to produce a biologically active collagen article. Various biologically active materials may be added to the aqueous acid solution prior to freezing. The collagen product may then be implanted into an animal or the like and the medication slowly released.

Abstract: A novel antibiotic, polynitroxin, is produced by the cultivation of a fermentation broth containing Nocardiopsis mutabilis Shearer sp. nov. ATCC 31520 in an aqueous nutrient medium under submerged aerobic conditions.